Clinical trials
Cell Therapy clinical trials
Below are recruiting cell therapy clinical trials, each written for real people, not researchers. We’re tracking 1,092 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07254806RecruitingPhase 3
Cell therapy for low back pain from disc disease
This study tests if injecting a special cell therapy into a damaged spinal disc can reduce chronic low back pain. It is for people who have had low back pain for at least 6 months and haven't gotten enough relief from other treatments like physical therapy or pain medication.
Birmingham, AlabamaAges 18–75 - NCT06011486RecruitingPhase 1
Expanded immune cells for CMV after stem cell transplant
This trial tests a treatment using specially grown immune cells (virus-specific lymphocytes) to fight a stubborn CMV infection that hasn't gotten better with usual medicines. It is for people who have had a stem cell transplant and need help controlling CMV.
São Paulo, São PauloAges 18–75 - NCT05417932RecruitingPhase 1/Phase 2
Cell therapy for hepatitis B–related liver cancer
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
New York, New YorkAges 18–70 - NCT06369389Recruiting
Real-world care for blood cancer patients receiving CAR-T therapy
This study looks at how patients with blood cancers are managed in real life when they receive CAR-T cell therapy. It helps doctors learn more about how well these treatments work outside of clinical trials.
Toulouse, CHU de ToulouseAges 18 years+ - NCT05905328RecruitingPhase 1/Phase 2
Drug to help prevent and treat cytokine release syndrome
This Phase 1/2 trial tests CTO1681 to help prevent and treat cytokine release syndrome (CRS) in people with DLBCL who are receiving CD19 CAR T-cell therapy. CRS is a potentially serious immune reaction that can happen after CAR T treatment, and this study aims to make that complication less severe or easier to manage.
Orange, CaliforniaAges 18 years+ - NCT06671275Enrolling by invitationPhase 1
Testing CUD005 Injection for Advanced Liver Cirrhosis
This study tests an injection called CUD005 for people with advanced liver cirrhosis that is causing complications. The goal is to see if it is safe and can help improve liver function.
Hefei, AnhuiAges 18–75 - NCT07505199RecruitingPhase 1
Immune cell therapy for advanced heart failure from blocked arteries
This early-phase study tests a new type of immune cell therapy (CAR-DC) for people with advanced heart failure due to blocked arteries. It aims to see if the treatment is safe and may help improve heart function.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07435779RecruitingEarly Phase 1
CAR-T cell therapy for severe ulcerative colitis
This trial tests a new treatment using your own immune cells (called CAR-T cells) to calm down the immune attack that causes ulcerative colitis. It is for people with moderate to severe colitis who have not gotten better with standard medicines.
GuangzhouAges 18–60 - NCT07120633Recruiting
CAR-T cell therapy plus BTK inhibitor for high-risk CLL/SLL
This trial tests a new approach for people newly diagnosed with high-risk CLL or SLL. It combines your own immune cells (CAR-T cells) with a targeted pill (BTK inhibitor) to try to attack the cancer more effectively. It may be an option if you have certain high-risk genetic features and haven't had prior chemotherapy.
Xuzhou, JiangsuAges 18 years+ - NCT07359014Recruiting
Dual-target car-t cell therapy for multiple myeloma
This trial tests a new type of immunotherapy using your own immune cells (called CAR-T cells) that are modified to attack two targets (CD19 and BCMA) on myeloma cells. It is for patients whose myeloma has come back or stopped responding to standard treatments.
HangzhouAges 18–75 - NCT07240207Recruiting
Studying immune cells in children's solid tumors
This trial analyzes the tumor environment in children with solid tumors to find better ways to use immune cells for treatment. It may help develop new cell-based therapies tailored to each child's tumor.
Pavia, PaviaAges 1 day–18 years - NCT07680803RecruitingPhase 2
Gene therapy for transfusion-dependent beta-thalassemia
This trial tests a one-time gene therapy using your own stem cells to help you produce healthy red blood cells and reduce or eliminate the need for regular blood transfusions. It is for people with transfusion-dependent beta-thalassemia who are between 3 and 35 years old.
Rome, LazioAges 3–35 - NCT06150365RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors (KSX01-TCRT)
This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.
BeijingAges 18–70 - NCT06665295Recruiting
THRIVE-CAR-T digital app for CAR-T patients
This trial tests a digital app to support patients receiving CAR-T therapy. It may help you track symptoms and communicate with your care team.
Boston, MassachusettsAges 18 years+ - NCT06710288RecruitingPhase 2
Immune cell therapy plus chemo for platinum-resistant ovarian cancer
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
El Segundo, CaliforniaAges 18–85 - NCT07298239RecruitingEarly Phase 1
CAR-NK cell therapy for advanced prostate cancer
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
Beijing, 不限Ages 18 years+ - NCT07680439RecruitingPhase 2
CAR T cell therapy study for children with DIPG brain tumor
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
Los Angeles, CaliforniaAges 1–26 - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT03984461RecruitingPhase 2
Platelet-rich treatment with joint fluid or bone cells for arthritis
This trial tests a joint treatment made from your own platelets (platelet-rich plasma, or PRP) combined with other biologic material (from fat tissue and/or bone marrow) to help osteoarthritis symptoms. It may be an option if you have early-to-moderate osteoarthritis in a major joint and meet safety requirements.
Kelowna, British ColumbiaAges 19–79 - NCT04190862RecruitingPhase 1
Cell therapy for simple anal fistulas
This Phase 1 study tests whether a donated-cell treatment (given with a minor procedure) can help heal simple anal fistulas. It mainly focuses on safety first, but may also look at how well the fistula closes.
New York, New YorkAges 18 years+ - NCT04318678RecruitingPhase 1
CD123 CAR T-cell therapy for relapsed leukemia and related cancers
This early-phase study tests a lab-made immune therapy (CD123 CAR T cells) for children and young adults up to age 21 whose cancer has come back or didn’t respond to treatment. The goal is to see if these CAR T cells can find and attack cancer cells that carry a marker called CD123.
Memphis, TennesseeAges Up to 21 years - NCT05146336Recruiting
CytoSorb registry for critically ill patients needing blood treatment
This registry collects information about critically ill patients who receive the CytoSorb 300 mL blood treatment. It may help doctors better understand when the treatment works best and when it should not be used.
KlagenfurtAges Any age - NCT05237986Recruiting
Study brain and thinking effects after CAR T therapy in youth
This study looks at how CAR T-cell treatment affects thinking, learning, and day-to-day brain function in children and young adults with certain blood cancers. You (and a caregiver) may complete online testing so researchers can track these changes over time and whether support is needed.
Los Angeles, CaliforniaAges 5 years+ - NCT05304208RecruitingPhase 1
Mesothelioma trial using immune cells plus surgery
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
Rotterdam, South HollandAges 18 years+
Hear when a new Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cell therapy?
- Yes. Clin2 currently lists 1,092 recruiting cell therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cell therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cell therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.